Codexis, Inc. (NASDAQ:CDXS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
Codexis, Inc. (the Company) held its Annual Meeting of
Stockholders on June14, 2017 in Redwood City, California. The
results of the matters voted on by the Companys stockholders are
set forth immediately below.
Proposal 1
To elect three Class I Directors to the Companys Board of
Directors (the Board) to hold office for three-year terms
expiring at the 2020 Annual Meeting of Stockholders or until
their respective successors are duly elected and qualified or
their earlier resignation or removal:
| Number of Votes | ||||||||||||
|
Name of Nominee |
For | Withheld | BrokerNon-Votes | |||||||||
|
Thomas R. Baruch |
23,774,009 | 1,711,193 | 16,809,585 | |||||||||
|
Pam P. Cheng |
25,337,914 | 147,288 | 16,809,585 | |||||||||
|
Patrick Y. Yang |
25,042,633 | 442,569 | 16,809,585 |
Proposal 2
To ratify the selection of BDO USA, LLP as the Companys
independent registered public accounting firm for the fiscal year
ending December31, 2017:
|
Number of Votes |
||||
|
For |
Against |
Abstain |
||
|
42,180,150 |
94,641 | 19,996 |
Proposal 3
To approve, on a non-binding, advisory basis, the following
resolution relating to the compensation of the Companys named
executive officers:
RESOLVED, that the compensation paid to Codexis, Inc.s named
executive officers, as disclosed in the proxy statement for the
2017 Annual Meeting of stockholders to Item402 of Regulation S-K,
including the disclosure under the heading Executive
Compensation, is hereby approved.
|
Number of Votes |
||||||
|
For |
Against |
Abstain |
BrokerNon-Votes |
|||
|
24,799,277 |
576,471 | 109,454 | 16,809,585 |
Proposal 4
To approve, on a non-binding, advisory basis, the frequency of
future advisory votes on compensation for the Companys named
executive officers:
|
Number of Votes |
||||||||
|
Every Three Years |
EveryTwoYears |
EveryOneYear |
Abstain |
BrokerNon-Votes |
||||
|
13,403,610 |
244,446 | 11,778,338 | 58,808 | 16,809,585 |
Consistent with the recommendation of the Board, a majority of
the shares represented in person or by proxy at the Annual
Meeting and entitled to vote voted to hold future advisory votes
on compensation for the Companys named executive officers every
three years, and the Company has determined to continue to hold
non-binding, advisory votes on compensation for the Companys
named executive officers every three years.
About Codexis, Inc. (NASDAQ:CDXS)
Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.
